Deuterated morphinan compounds for treating agitation
AssigneeConcert Pharmaceuticals, Inc.
InventorsRoger D. Tung, Philip B. Graham
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disorders with such a morphinan compound in combination with quinidine, or pharmaceutically acceptable salt of either or both thereof.
Claims11
1-14. (canceled).
A method of treating a disease or disorder selected from the group consisting of diabetes, epilepsy, and depression, comprising administering to a subject in need thereof an effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is selected from —CH3, —CH2D, —CHD2, and —CD3;
- and
- R2 is selected from CH3, CH2D, CHD2, and CD3;
- provided that either R1 or R2 comprises at least one deuterium atom;
- and quinidine or a pharmaceutically acceptable salt thereof;
- and a pharmaceutically acceptable carrier.
22-23. (canceled).
Dependencies are inferred from the claim text.